|
Fortis Healthcar launched ‘Fortis Institute of Genomic Medicines’, a pioneering centre dedicated to harnessing the power of genomic science to transform patient care across India. Backed by Fortis’ advanced clinical ecosystem and Agilus Diagnostics’ extensive national footprint, the institute will bring together a multi-disciplinary team of medical experts including molecular haematology, oncology, neurology, paediatrics, pathology, genomic scientists alongwith bioinformaticians and AI (artificial intelligence) engineers.
Genomics is transforming the future of modern medicine and treatment modalities across specialties – oncology, cardiology, neurology. Onco-genomics will help clinicians decode the genetic drivers of cancer, enabling targeted therapies that are more effective and less toxic than traditional one-size-fits-all treatments. Cardio-genomics will empower the early detection of inherited cardiac conditions, crucial for families with a history of sudden cardiac arrest, unexplained heart failure, or congenital heart disease. Meanwhile, Neuro-genomics will offer new hope for patients with complex neurological disorders, using gene-based insights to improve diagnosis and personalize interventions for conditions like epilepsy, Parkinson’s and rare neurodevelopmental syndromes. The power of Genomics, has already delivered life-changing outcomes: a leukaemia patient, initially headed for a transplant, received a new course of treatment following a precise genetic diagnosis; a woman with a silent hereditary cancer risk underwent genomic screening, leading to early detection and preventive care for three family members; and a lung cancer patient with a previously undetected MET-ST7 fusion (a genetic alteration)—identified solely through Fortis’ Next-Generation Sequencing (NGS)—is now thriving on targeted therapy.
Anil Vinayak, group chief operating officer, Fortis Healthcare said, “By integrating genomics into our core offerings, we are enhancing our ability to deliver personalized, data-driven care while strengthening our clinical leadership in clinical innovation. This initiative reinforces our long-term commitment to investing in future-ready technologies that improve patient outcomes, support clinical excellence, and redefine the standards of care across the healthcare ecosystem.”
Dr. Ritu Garg, chief innovation and growth officer, Fortis Healthcare said, “We recognize that the future of medicine lies in precision and personalization. This institute reflects our vision to integrate cutting-edge science with clinical excellence, enabling us to drive better patient outcomes and redefine standards of care. As leaders in the healthcare ecosystem, we are committed to fostering innovation that is scalable, sustainable, and deeply impactful."
Yash Rawat, VP & facility director, Fortis Memorial Research Institute, Gurugram said, "Genomic testing is revolutionizing the way we approach health and chronic ailments. It will be crucial in curbing non-communicable diseases by enhancing early disease detection, treatment precision, and risk assessment. Whether it’s a child with unexplained anaemia, a woman with a family history of breast cancer, or a lung cancer patient needing targeted therapy, genomics changes the game by personalizing the treatment approach. By analyzing one’s DNA, one can uncover vital information about one’s inherited risk factors, how one metabolizes medications, and one’s susceptibility to certain diseases.”
Soon Fortis will also launch a Genomics-informed health registry, setting a new benchmark in precision medicine along with India’s first AI-powered genomic reporting platform designed specifically for Indian clinicians as per international recommendations by ACMG (American College of Medical Genetics and Genomics), AMP (Association for Molecular Pathology), and ASCO (American Society of Clinical Oncology) - which will be compliant, clinically relevant, and intuitively designed for seamless integration into medical practice.
|